MA34939B1 - Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation - Google Patents

Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation

Info

Publication number
MA34939B1
MA34939B1 MA35350A MA35350A MA34939B1 MA 34939 B1 MA34939 B1 MA 34939B1 MA 35350 A MA35350 A MA 35350A MA 35350 A MA35350 A MA 35350A MA 34939 B1 MA34939 B1 MA 34939B1
Authority
MA
Morocco
Prior art keywords
diseases
prevention
treatment
heterocyclylbenzyl
pyrazoles
Prior art date
Application number
MA35350A
Other languages
English (en)
Inventor
Michael Härter
Hartmut Beck
Susanne Greschat-Schade
Peter Ellinghaus
Kerstin Unterschemman
Joachim Schuhmacher
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44063276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34939(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA34939B1 publication Critical patent/MA34939B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux dérivés de 1-[3-(hétérocyclyl)benzyl]-1H-pyrazole, leur procédé de fabrication, leur utilisation pour le traitement et/ou la prévention de maladies ainsi que leur utilisation pour la fabrication de médicaments pour le traitement et/ou la prévention de maladies, en particulier pour le traitement et/ou la prévention de maladies hyperprolifératives et angiogéniques telles que ces maladies qui sont provoquées par une adaptation métabolique à des états hypoxiques. De tels traitements peuvent avoir lieu en tant que monothérapie ou aussi en combinaison avec d'autres médicaments ou d'autres mesures thérapeutiques.
MA35350A 2010-05-08 2011-05-03 Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation MA34939B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10004855 2010-05-08
PCT/EP2011/057021 WO2011141326A1 (fr) 2010-05-08 2011-05-03 Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation

Publications (1)

Publication Number Publication Date
MA34939B1 true MA34939B1 (fr) 2014-03-01

Family

ID=44063276

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35350A MA34939B1 (fr) 2010-05-08 2011-05-03 Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation

Country Status (25)

Country Link
US (2) US20130172311A1 (fr)
EP (1) EP2569312B1 (fr)
JP (1) JP5727002B2 (fr)
KR (1) KR20130108997A (fr)
CN (1) CN103003269B (fr)
AR (1) AR081368A1 (fr)
AU (1) AU2011252223A1 (fr)
BR (1) BR112012028651A2 (fr)
CA (1) CA2798375A1 (fr)
CO (1) CO6640218A2 (fr)
CR (1) CR20120570A (fr)
CU (1) CU20120157A7 (fr)
DO (1) DOP2012000284A (fr)
EA (1) EA201291167A1 (fr)
EC (1) ECSP12012288A (fr)
ES (1) ES2462522T3 (fr)
IL (1) IL222851A0 (fr)
MA (1) MA34939B1 (fr)
MX (1) MX2012012960A (fr)
PE (1) PE20130228A1 (fr)
SG (1) SG185459A1 (fr)
TN (1) TN2012000531A1 (fr)
TW (1) TW201200510A (fr)
UY (1) UY33369A (fr)
WO (1) WO2011141326A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759258B2 (en) * 2007-05-01 2014-06-24 Hill's Pet Nutrition, Inc. Methods and compositions for diagnosing osteoarthritis in a feline
CN101765596B (zh) * 2007-05-18 2015-04-29 拜耳知识产权有限责任公司 用于治疗过增生症状和与血管生成有关疾病的缺氧诱导因子(hif)抑制剂
ES2462522T3 (es) * 2010-05-08 2014-05-23 Bayer Intellectual Property Gmbh Heterociclilbencilpirazoles sustituidos y uso de los mismos
MX352351B (es) 2012-07-02 2017-11-21 Monsanto Technology Llc Procesos para la preparacion de 1,2,4-oxadiazoles 3,5-disustituidos.
EP2888253A4 (fr) 2012-08-24 2016-01-06 Univ Texas Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
EP2888255B1 (fr) 2012-08-24 2018-07-18 Board of Regents, The University of Texas System Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
WO2014031928A2 (fr) * 2012-08-24 2014-02-27 Philip Jones Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
EP3110420B8 (fr) 2014-02-25 2019-07-10 Board of Regents, The University of Texas System Sels de modulateurs hétérocycliques de l'activité de hif pour le traitement de maladies
US10191597B2 (en) 2015-06-30 2019-01-29 Synaptics Incorporated Modulating a reference voltage to preform capacitive sensing
KR102544307B1 (ko) * 2017-01-13 2023-06-15 닛산 가가쿠 가부시키가이샤 방향족 디아민 화합물 전구체의 제조 방법
CN115944626B (zh) * 2022-12-08 2024-04-19 桂林医学院附属医院 小分子化合物在制备抗缺氧或缺血再灌注损伤药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610726B2 (en) * 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
WO2004089303A2 (fr) 2003-04-03 2004-10-21 Merck & Co., Inc. Modulateurs au pyrazole a substitution diaryle du recepteur-5 de glutamate metabotropique
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
WO2007065010A2 (fr) 2005-12-02 2007-06-07 Hif Bio, Inc. Composes anti-angiogenese
CN101765596B (zh) * 2007-05-18 2015-04-29 拜耳知识产权有限责任公司 用于治疗过增生症状和与血管生成有关疾病的缺氧诱导因子(hif)抑制剂
DE102008057344A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
CA2743536A1 (fr) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Composes aryles substitues par heterocycle comme inhibiteurs de hif
EP2356112A1 (fr) * 2008-11-14 2011-08-17 Bayer Schering Pharma Aktiengesellschaft Composés hétéroaromatiques pour une utilisation comme inhibiteurs de hif
EP2202232A1 (fr) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. Dérivés du 1,2,4-oxadiazole et leur application thérapeutique
WO2010085584A1 (fr) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Dérivés de pyrazole-1,2,4-oxadiazole en tant qu'agonistes de sphingosine-1-phosphate
ES2462522T3 (es) * 2010-05-08 2014-05-23 Bayer Intellectual Property Gmbh Heterociclilbencilpirazoles sustituidos y uso de los mismos

Also Published As

Publication number Publication date
ES2462522T3 (es) 2014-05-23
CR20120570A (es) 2013-04-22
IL222851A0 (en) 2012-12-31
MX2012012960A (es) 2012-12-17
AU2011252223A1 (en) 2012-12-06
ECSP12012288A (es) 2012-12-28
DOP2012000284A (es) 2013-03-31
CU20120157A7 (es) 2013-03-27
BR112012028651A2 (pt) 2016-08-09
PE20130228A1 (es) 2013-03-15
SG185459A1 (en) 2012-12-28
CO6640218A2 (es) 2013-03-22
JP2013526497A (ja) 2013-06-24
WO2011141326A1 (fr) 2011-11-17
EA201291167A1 (ru) 2013-05-30
CA2798375A1 (fr) 2011-11-17
US20130172311A1 (en) 2013-07-04
CN103003269A (zh) 2013-03-27
EP2569312A1 (fr) 2013-03-20
TN2012000531A1 (en) 2014-04-01
AR081368A1 (es) 2012-08-29
KR20130108997A (ko) 2013-10-07
TW201200510A (en) 2012-01-01
US8470811B2 (en) 2013-06-25
UY33369A (es) 2011-12-01
JP5727002B2 (ja) 2015-06-03
CN103003269B (zh) 2015-11-25
US20120028950A1 (en) 2012-02-02
EP2569312B1 (fr) 2014-03-26

Similar Documents

Publication Publication Date Title
MA34939B1 (fr) Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation
MA34019B1 (fr) Aryltriazolone liée à un bis-aryle et son utilisation
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
MA31167B1 (fr) Inhibiteurs de l'activite de akt
EA201170043A1 (ru) Комбинация пилокарпина и метимазола для лечения заболевания шарко-мари-тута и связанных с ним нарушений
MA33538B1 (fr) Nouveaux antagonistes pyrimidine et triazine de l'hepcidine
MA33279B1 (fr) Compositions et procédés pour l'augmentation de la croissance des muscles
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
WO2012045882A3 (fr) Composition pharmaceutique
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
EA201270480A1 (ru) Новые соединения
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
WO2009082038A3 (fr) Antagonistes des récepteurs ampa et zonisamide pour le traitement de l'épilepsie
MA34517B1 (fr) Promédicaments comprenant un conjugué exendine-lieur
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
WO2012136969A3 (fr) Traitements ophtalmiques
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
WO2009106980A3 (fr) Dérivés d'indazole
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
MA30090B1 (fr) Utilisation d'un antagoniste de CB1 pour le traitement des effets secondaires et des symptômes négatifs de la schizophrénie
EP2548552A3 (fr) Ensemble de titration pour 1-amino-alkylcyclohexanes
WO2010086828A3 (fr) Anticorps monoclonaux agonistes anti-trkb